Opko Health to launch mid-stage study of Rayaldee in COVID-19

The FDA has signed off on a 166-subject Phase 2 clinical trial, REsCue, evaluating OPKO Health’s (NASDAQ:OPK) Rayaldee (calcifediol) in patients with mild-to-moderate COVID-19.

Participants will receive either Rayaldee or placebo for four weeks. The primary objective is to raise and maintain serum total 25-hydroxyvitamin D within a range of 50-100 ng/mL in order to mitigate COVID-19 severity.

https://seekingalpha.com/news/3578950-opko-health-to-launch-mid-stage-study-of-rayaldee-in-covidminus-19